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ACE and Subarachnoid Hemorrhage:
Strategies for Genetics of Stroke
To the Editor:
I thank Slowik et al for their article investigating the
angiotensin-converting enzyme (ACE) insertion/deletion (I/D)
polymorphism in subarachnoid hemorrhage (SAH).1 I wish to
comment on several aspects of this article related to the design
of genetic association studies for complex disorders such as
SAH, which are important in interpreting their findings. It is
impressive to note the high odds ratios achieved, however this
study was less than half the size of the one it aimed to
confirm.2 The populations of the 2 studies were of European
origin and the allele frequencies were also similar. Using
calculations previously described3 and the data from Kera-
matipour et al,2 an estimated sample size of 600 subjects is
required to show the presence of an association of ACE I/D
with SAH with 80% power. It is surprising that Slowik et al
achieved twice as high an odds ratio with half the sample size.
The small sample size of this study could have resulted in a
type 1 error.
ACE I/D polymorphism has been extensively studied in
several disorders with conflicting results. Interestingly, Zhu et
al showed that the I/D polymorphism is not functional and its
association with elevated plasma ACE levels is secondary to a
linkage disequilibrium (LD) effect.4 We recently showed this
to be the case for the association of the I/D polymorphism
with essential hypertension as well.5,6 To verify the effect of
a gene it is important to genotype several single nucleotide
polymorphisms (SNPs) across the gene, study the structure of
the haplotype block and look for associations with the
haplotypes, which considerably increases the power of a
case-control study. Moreover, improvised study designs such
as sib pair and TDT-trios are formidable tools for teasing out
the genetic architecture of complex disorders. Elaborate
algorithms exploring the combinatorial effects of SNPs in
several candidate genes across the genome have recently
become available and can add power to the analysis.7 Using
novel study designs entire pathways, such as the renin-angio-
tensin system (RAS), can be explored in complex disorders
such as SAH. This is important as some components of RAS
increase angiotensin II formation whereas others decrease it.8
It is also worthy to collect details of disease characteristics
which may serve as covariates in subsequent allele, genotype
and haplotype analysis. The study design can be enhanced by
including intermediate phenotypes in the study.9 Recently,
genome-wide SNP analysis using microarrays has brought
linkage analysis for complex disorders within the realm of
reality,10 provided suitable pedigrees are available.
Without such elaborate efforts it will be difficult to mean-
ingfully interpret results of genetic association studies for
complex disorders. Studies of human polymorphisms had a
modest presence in 1980 with just over 100 publications.
After the explosive entry of ACE I/D in 199211 and ApoE -4
in 199312 in the complex disease arena, there was an expo-
nential rise in the studies of human polymorphisms, most
being association studies. Approximately 3500 such studies
are now published annually in indexed journals. Making sense
of such a large number of studies, several presenting contra-
dictory findings, is a colossal task. Unless well-determined
guidelines are followed, and robust study designs and appro-
priate sample sizes are used, many resources will go to waste.
Also, a majority of the genome will remain unexplored in
most disorders, and only a few loci will be investigated
repeatedly with no additional information gained. It is impor-
tant that we realize the significance of well-planned genetic
association studies aimed at stroke and associated complex
disorders. In light of this, the National Institutes of Health
funded Siblings with Ischemic Stroke Study is much appreci-
ated.13 Additionally, a Stroke Consortium could be made which would
allow the use of DNA and other resources to investigators on approval
of a proposal in a similar fashion as the Framingham Heart Study.14 We
must act before it is too late.
Mohammad Saeed, MD
Department of Biological and Biomedical Sciences
Aga Khan University
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Response:
We thank Dr Saeed for his letter emphasizing a very important
aspect concerning the design of genetic studies, ie the calculation
of the power of a study and the number of patients included in the
control and case groups needed to provide replicable results.
Interestingly, while analyzing the studies that assess the signif-
icance of different polymorphisms in a variety of stroke etiolo-
gies, which have been published in Stroke during the last five
years, we found that this aspect of methodology was addressed
only in a few cases. In general, the previous authors published in
Stroke calculated the required number of cases and controls to
achieve the power of 80% (P0.05). This was based on allele or
genotype frequencies in the populations to achieve a given
minimum odds ratios,1 relative risk by allele,2 or the proportion
of the studied alleles in cases and controls.3 Other journals, such
as Neurology4 and Human Genetics5 have already published the
guidelines for genetic association studies in humans. We feel it
would be reasonable to prepare such guidelines for publication in
Stroke. The information regarding the power of a study should be
provided, in a uniform fashion, within the methodology section
of all articles related to this topic.
A very important aspect in the design of genetic association
studies (or any clinical study, for that matter) is the ability to
generate significant and replicable results while keeping within
budget constraints. It is well known that the population frequency
of the II genotype, and not I allele, of the angiotensin-converting
enzyme (ACE) gene is approximately 25% (23.7% in English
patients6 and 23.4% in our controls7). Bearing this in mind, we
calculated that having 90 patients with aneurysmal subarachnoid
hemorrhage and 128 controls, we would be able to obtain
statistically significant differences between the groups if the odds
ratio was 2.5, assuming the study’s achievable power to be
80%, and P0.05. In our study, type I error (probability of
rejecting true H0 hypothesis) was 0.00001, which is very low.
It is commonly known that ACE gene insertion/deletion
polymorphism, because it is an intronic marker, may be func-
tionally neutral, but may be in linkage disequilibrium with other
(functional) mutations within ACE or another gene.8 The genetic
association studies, such as we performed, generally answer the
question as to whether the target allele or genotype remain risk
factors for the disease, but they do not answer the question, does
the causal relationship exist between them? We can only spec-
ulate therefore whether such a causal relationship exists. We
have already planned to expand our studies of the ACE gene,
examining several single nucleotide polymorphisms across the
gene, and calculating association with haplotype(s). We agree
with Dr Saeed that introducing genome-wide single nucleotide
polymorphism analysis using microarrays is an approach that
will ultimately enable study of complex disease mechanisms in
greater detail.
Agnieszka Slowik, MD
Anna Borratynska, MD
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Is Perimesencephalic Nonaneurysmal
Hemorrhage of Venous Origin?
To the Editor:
We read with great interest the article by van der Schaaf and
colleagues1 in the July 2004 issue of Stroke in which the authors
sought to assess the contribution of venous drainage patterns in
the etiology of perimesencephalic hemorrhage (PMH). PMH,
defined by a negative 4-vessel angiographic study as bleeding in
the cisterns around the midbrain, is associated with an excellent
outcome.2 Using computed tomography angiography, van der
Schaaf and colleagues found that patients with PMH had prim-
itive venous drainage directly into dural sinuses instead of via the
vein of Galen, as with patients having aneurysmal subarachnoid
hemorrhage. They also observed that the side of the PMH related
to the side of the primitive drainage. They concluded that these
results support the venous origin of PMH. Although van der
Schaaf and colleagues found differences in the venous drainage
of these patients, they neglected to present direct evidence
showing that primitive venous drainage led to hemorrhage
around the midbrain. They speculated that direct venous pressure
from the dural sinus might cause the rupture of the perimesen-
cephalic veins. However, their speculation is not substantiated
because other cerebral veins with direct connection to the dural
sinus never rupture under normal circumstances. Moreover, if
this variation of venous drainage were a cause of bleeding, it
would have a high chance of rebleeding in the follow-up because
venous drainage is not easily changed.
We would like to bring to the authors’ attention our study of
PMH3 in which small bulges on the basilar artery were found in
2 patients by 3D rotational angiography. These lesions were
thought to be intramural hematomas due to arterial dissection and
to be responsible for the hemorrhage in each case. This finding
matches the distribution of the hematomas, and the spontaneous
healing of the dissection could explain the absence of rebleeding.
The small bulges showed spontaneous resolution, but they were
too small to be detected by computed tomography angiography,
such as that employed by van der Schaaf and colleagues.
Therefore, we would like to emphasize that some of the PMH
were of arterial origin. Nonetheless, the study by van der Schaaf
and colleagues, which focuses on venous drainage, provides an
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important contribution to the literature. We congratulate the
authors on their careful observations.
Yuji Matsumaru, MD, PhD
Kiyoyuki Yanaka, MD, PhD
Akira Matsumura, MD, PhD
Department of Neurosurgery
Institute of Clinical Medicine
University of Tsukuba
Tsukuba, Ibaraki, Japan
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Venous Drainage in Perimesencephalic
Hemorrhage: Is Perimesencephalic
Nonaneurysmal Hemorrhage
of Venous Origin?
Response:
We appreciate the interest of Dr Matsumaru and colleagues in
our article on the venous drainage patterns in the etiology of
perimesencephalic hemorrhage (PMH).1
Dr Matsumaru focuses our attention on their observation in 2
patients with a perimesencephalic pattern of hemorrhage, who
had small bulges on the basilar artery that disappeared on
follow-up imaging. These bulges were supposed to be intramural
hematomas due to arterial dissection, and were not visible on
standard DSA but only on the 3-D angiography.2 The authors
emphasized that some of the patients with a PMH might have had
an arterial origin.
We are aware that in patients with a perimesencephalic pattern
of hemorrhage, the cause is of arterial (vertebrobasilar) origin in
5% of the cases.3 We also agree that an abnormal venous
drainage is not the definitive cause in all patients with a PMH.
However in patients with a unilateral primitive variant, the blood
was always found on the side of the primitive drainage, which
suggests a relation between the primitive venous variant and the
bleeding. Four patients in our series had a “normal” venous
drainage system in both hemispheres. We cannot substantiate the
suggestion that in these 4 patients the PMH was caused by
bleeding from small intramural hematomas. None of these
patients underwent DSA.4 Three of these 4 patients were scanned
on a single-slice CTA scanner; the resolution of this scanner does
allow the detection of such small bulges. The fourth patient,
however, was scanned on a multislice CT scanner. Multislice
(MS) CTA provides a high resolution and small vascular details
can be detected.5 In this patient we reviewed the CTA using
multiplanar reconstruction in 3 directions and maximum inten-
sity projection, but we did not find any irregularity on the vessel
wall of the basilar artery.
Dr Matsumaru and coauthors also mention that other cerebral
veins with direct connection to the dural sinus never rupture
under normal circumstances and therefore think that our specu-
lation that direct venous pressure from the dural sinus might
cause rupture of the perimesencephalic veins is not substantiated.
The authors also point out that if this variation in venous
drainage were a cause of bleeding, it would have a high chance
of rebleeding because the venous system is not easily changed.
We would like to emphasize that primitive variants lack fusion
of the 3 primitive veins during the embryologic development of
the Galenic system.6 This deficiency of anastomosis might make
these vessels more prone to rupture due to sudden increase in
venous pressure. Even though other veins do connect directly to
the dural sinuses, the perimesencephalic fine venous network is
usually protected from sudden pressure changes by the drainage
from the basal vein of Rosenthal through the Galenic system into
the straight sinus. It is possible that a more direct connection to
a dural sinus makes this network more vulnerable to pressure
changes. Some of the primitive veins cross the tentorial margin,
which might lead to torsion or friction and therefore make these
primitive variants even more prone to rupture. We speculate that
the spontaneous healing of the venous system by fibrous tissue
firms the vessel wall of the vein on its weakest point, thereby
preventing it from rerupture.
Arterial dissections are a frequent cause of the hemorrhage in
patients with subarachnoid hemorrhage, but without an aneurysm
on angiography.7 In most patients with subarachnoid hemorrhage
from intracranial dissections, the pattern of hemorrhage is not
confined to the perimesencephalic cisterns, but comparable to an
aneurysmal pattern of hemorrhage7 Moreover, intracranial dis-
sections leading to a subarachnoid hemorrhage have a 30% risk
of rebleeding.8 These characteristics are unlike those from PMH,
and we do not think that arterial dissections are a frequent cause
of PMH. The relatively benign symptoms at onset, the clinical
course without rebleeding or secondary ischemia, and the local-
ized pattern of hemorrhage favor a venous source in the majority
of these patients. The observation of Dr Matsumaru et al offers
an interesting vision in the etiology of PMH, which may hold
true for some patients with a perimesencephalic pattern of
hemorrhage. The higher resolution of the MS CT scanners and
3D angiography will provide more insight on this finding in the
future.
I.C. van der Schaaf, MD
B.K. Velthuis, MD
Department of Radiology
University Medical Center Utrecht
Utrecht, The Netherlands
A. Gouw, MSc
G.J.E. Rinkel, MD
Department of Neurology
University Medical Center Utrecht
Utrecht, The Netherlands
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Contrast Ultrasound Techniques in the
Detection and Quantification of Patent
Foramen Ovale: Myth Versus Reality
To the Editor:
I read with great interest the study of Anzola et al. The authors
declared contrast-enhanced transcranial Doppler (ce-TCD) as the
ideal tool to follow up patients after interventional device
closure.1
Data show a high correlation between ce-TCD and contrast
enhanced transesophageal echocardiograpgy (cTTE) which is the
current “gold standard” for detection of a right-to-left shunt
through a patent foramen ovale (PFO), although there is a highly
reported interobserver and intraobserver variability of the latter.2
Furthermore, there are major methodological limitations of these
techniques that need to be addressed.
The numbers of microbubbles reaching the brain can be
quantified by ce-TCD, however the therapeutic impact of this
information is unknown. There is no prospective study (neither
by ce-TCD nor by cTEE) demonstrating that the amount of
contrast shunting has any relevance for the outcome of these
patients.2,3 We have previously shown that the amount of
contrast shunting does not correlate with the size of the PFO
measured by 2-dimensional TEE or invasively by balloon
sizing.4
Devuyst and colleagues reported that the amount of right-to-
left contrast shunting through a PFO measured my ce-TCD
mainly depends on strain rate and duration of the Valsalva
maneuver.5 As Anzola et al did not perform the ce-TCD follow
up under these controlled conditions, 2 contrast studies may lead
to different results in the same patient even if the PFO would not
have been closed.
It has been shown previously that ce-TCD with saline contrast
can remain positive, even without difference in the intensity,
after complete occlusion of anatomical arteriovenous
malformations.6
According to recent findings one must accept that there is no
rigid diagnostic time window for differentiation between inter-
atrial and intrapulmonary shunts.7–10 And there is evidence that
physiological arteriovenous intrapulmonary shunts do exist in
most healthy humans.11 As we know so far, shunting through this
dynamic vascular network is influenced on a variety of patient
dependent and methodological reasons like cardiac output, blood
pressure, or drugs.11–13
Before and after PFO-closure we recommend, irrespective of
the results of a ce-TCD, to perform a TEE examination, as it
provides direct anatomic information regarding the site and
nature of the shunt and regarding the device to exclude a
thrombus formation.14
Herwig W. Schuchlenz, MD
Graz-West Hospital
Graz, Austria
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Dr Schuchlenz’s letter seems to put a special emphasis on the
lack of specificity of contrast-enhanced transcranial Doppler
(ce-TCD) in differentiating the source of a right-to-left shunt
(RLS), namely patent foramen ovale (PFO) versus pulmonary
fistulas. In our opinion, however, instead of showing limitation,
this is an argument in favor of transcranial Doppler (TCD) as an
ideal tool for screening and follow-up purposes inasmuch as
paradoxical embolism is suspected responsible for otherwise
cryptogenic strokes. It is commonly recognized that TCD detects
more RLSs than transesophageal echocardiography (TEE), not
only because TEE may miss pulmonary fistulas but also because
even in cases of PFO, the patient may be unable to perform a
Valsalva strain valid enough to divert bubbles from the right to
the left atrium across the PFO.1 This raises some doubt on the
concept of TEE as the gold standard for PFO detection.
There are at least 2 studies that have shown a relationship
between the amount of RLS as assessed with TCD and stroke
occurrence or relapse.2,3
The ce-TCD test was always performed in controlled condi-
tions following the recommendations of the Consensus of
Venice4 and the strength of Valsalva was regulated so as to
obtain a reduction of at least 20% of the spectral amplitude. For
these reasons we believe that the bubble load assessed in the
middle cerebral arteries at follow-up testing truly reflected the
degree of residual shunt.5
The fact that TCD (and TEE) remain positive after apparently
successful embolization of a pulmonary arteriovenous malforma-
tion (AVM) in a patient with Rendu-Osler disease, as is reported
in Yeung et al6 is not surprising for at least 2 reasons. First, the
embolization of a macroscopic pulmonary AVM may not abolish
the local RLS. Second, Rendu-Osler disease entails the presence
of multiple microscopic AVMs that can escape angiography but
nonetheless bring about a cumulatively significant RLS.
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Physiological intrapulmonary shunts are activated after pro-
longed strenuous exercise7 whereas ce-TCD requires a simple
Valsalva strain for a few seconds.
None of the patients in our series was under the effect of drugs
likely to affect intrapulmonary shunts.8,9
Our policy is to perform TEE after TCD demonstrates RLS to
confirm the intracardiac site before PFO closure and to repeat it
postprocedurally only in those patients in whom TCD has shown
a significant residual shunt or in those who relapse after
successful closure. Routine use of TEE to detect thrombus
formation in the left atrium does not seem justified in asymp-
tomatic patients given the very low absolute incidence of
thrombus formation with the more recent devices.10
G.P. Anzola, MD
E. Morandi, MD
Service of Neurology
S. Orsola Hospital FBF
Brescia, Italy
F. Casilli, MD
E. Onorato, MD, FSCAI
Department of Cardiology
Humanitas Gavazzeni Clinic
Bergamo, Italy
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White Matter Hyperintensities: Pearls and
Pitfalls in Interpretation of MRI Abnormalities
To the Editor:
Atwood et al acknowledge that the pathophysiology of white
matter hyperintensities (WMH) is uncertain and underscore the
possibility of ischemic etiology, especially in the elderly.1 These
authors regard WMH as an excellent marker of brain aging and
emphasize their heritability in patients with negative correlation
with cerebrovascular brain injury.
WMH are neither age-specific nor generally heritable, having
been found in both sexes in hypertensive encephalopathy, puer-
peral eclampsia, migraine, and therapy with cyclosporin,
interferon-, and tacrolimus.2,3 Kruit and coworkers found
WMH in MRI only in women migraine patients,2 which likely
reflects an investigational artifact. Atwood et al did not exclude
hypertensive and migraine patients from their analysis, which
prominently confounds their interpretation of WMH as indicative
of brain aging.
An important pathophysiological clue to the nature of WMH is
offered by the characteristic difference in the distribution of
infarcts and deep WMH in migraine patients. Predominantly
posterior circulation territory (PCT) migrainous infarcts in con-
trast to anterior circulation infarcts in embolic or atherosclerotic
thrombotic strokes in general are likely related to rheological
factors. Anatomical vulnerability of the posterior cerebral artery
renders it particularly susceptible to vasospastic influences in
migraine patients.4 The rare occurrence of neuroanatomically
nonlateralizing—in relation to headache or aura—PCT infarcts
in younger migraine sufferers might represent an uncommon
complication of an adaptive vasospasm that rarely reduces
perfusion critically in a particularly labile region.4
Diffuse nonlateralizing distribution of deep WMH unaffected
by triptan use2 indicates that WMH do not reflect the outcome of
vasospastic ischemia. Also, local changes during migraine at-
tacks, eg, excessive neuronal activation or excitotoxicity,2 should
logically manifest lateralizing WMH. Deep WMH, in contrast to
infarcts, likely resolve totally along with resolution of symptoms
and signs after treatment of hypertension or withdrawal (or
reduction of dose) of immunosuppressive agents.3 Vasogenic
cerebal edema probably underlies WMH in hypertensive enceph-
alopathy; breakdown of the blood–brain barrier has been shown
in human and in rat models.3 Attack-related, inconsistently-
lateralized, and prolonged (48 hours) hyperperfusion prevails
in the cerebral cortex, thalamus, and basal ganglia in migraine.5
In direct contrast to infarcts, WMH probably result from intense
but self-limited cerebral hyperperfusion. I propose that WMH are
markers of transient breakdown of the blood–brain barrier rather
than aging.
The heritability of WMH volumes is an intriguing feature.1
The decline in heritability estimates after age 601 indicates the
nongenetic nature of this observation. Another indicator of the
nongenetic nature of WMH is the absence of correlation with
aging in women despite higher heritability. Migraine is more
prevalent in women than in men, from approximately age 14.6
Breakdown of the aging-marker hypothesis for WMH in women
may relate to migraine headaches. Finally, heritability of WMH
may relate more to heritability of hypertension or migraine or
both. In the absence of any link to cerebrovascular disease, the
menopause probably has no independent bearing on WMH.
Spontaneous resolution likely underlies significantly smaller
WMH volumes at younger age, especially in women,1 in which
cohort the highest prevalence of migraine can be expected. These
authors also hope to establish a genetic link between WMH and
silent brain infarctions.1 Unless the resolution or otherwise of
WMH is established prospectively, it is premature to link this
MRI finding with cerebrovascular ischemic disease. Cross-
sectional studies of WMH cannot establish vascular-related
genetic influences, as has been suggested.1 Assumption of the
genetic model for WMH1 is probably incorrect.
Vinod K. Gupta, MD
Dubai Police Medical Services
Dubai, United Arab Emirates
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Response:
In his letter to the editor, Dr Gupta argues that white matter
hyperintensities (WMH) are neither age-specific nor heritable.
As evidence in support of this argument, he expands on an
already lengthy list of causes for WMH in order to underscore
the nonspecific nature of these phenomena. He then focuses on
the distribution of WMH in migraine patients to support his
hypothesis that WMH represent transient breakdown of the
blood–brain barrier rather than the aging process per se. Finally,
Dr Gupta concludes that our data do not support the heritability
of WMH.
In response to his observations that WMH should be consid-
ered nonspecific, we agree completely. Many diseases lead to
WMH. We must note, however, that most of the causes identified
by Dr Gupta are extremely rare in a community-based population
such as the Framingham Heart Study, suggesting that the overall
influence of these diseases is likely to be extremely low.
Regarding his hypothesis that WMH reflect a breakdown of the
blood–brain barrier, there is ample evidence to support this,
particularly in multiple sclerosis; but again, the prevalence of this
disease in a healthy population is so low as to be negligible, and
all known subjects with multiple sclerosis or other neurological
diseases affecting white matter were systematically excluded. Dr
Gupta does note that transient breakdown of the blood–brain
barrier may be common to migraine, but this would not explain
our findings as migraine declines in prevalence with advancing
age. In addition, we note that age-related increases in WMH
volume are one of the most consistent findings in studies that
limit analysis to extremely healthy individuals.1–4 From these
data, we conclude that age, in fact, does relate to WMH volumes
for the general population. In the manuscript, however, we do
caution that age-related cardiovascular diseases such as systolic
hypertension are also likely to contribute to the extent of WMH,5
leading us to suggest that WMH may serve as a phenotypic
marker for both aging and disease.
Dr Gupta also argues that our data do not conclusively show
heritability of WMH. As evidence for this, he notes the decline
in heritability after age 60. He further concludes that our data
state that there is no correlation with age and WMH among
women. Regarding the decline in heritability seen with advanc-
ing aging, it is important understand that this was a family-based
study. With advancing age, individuals are less likely to have
informative family members to estimate heritability, leading to
the possibility of spurious findings such as that seen with the
oldest woman of this study. In fact, other than this anomaly, the
heritability estimates were remarkably consistent at about 0.60
across both age and gender differences. Dr Gupta’s second
argument for heritability reflects an apparent misunderstanding
of the data. Age was not a significant covariate for the herita-
bility estimates in women, but the correlation between age and
WMH was high (r0.50) and nearly identical for men and
women.
We appreciate Dr Gupta’s critical review of our manuscript,
but continue to believe that WMH lesions are strongly heritable.
We also continue to believe that this heritability probably reflects
both the processes of aging and concurrent disease and hope that
WMH will serve as a new phenotype to explore the genetics of
both processes.6
Charles DeCarli, MD
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Nicotinamide Attenuates Focal Ischemic Brain
Injury: Meta-Analysis or Mechanism
of Protection
To the Editor:
We read with great interest the recent article by Macleod et al.1
They have shown a highly significant neuroprotective effect of
nicotinamide on experimental stroke using the technique of
systematic review or meta-analysis. The message is clear, and we
believe this approach is useful and fairly robust in terms of
statistical power. However, I would like to point out a possible
pitfall of their overview. Nicotinamide, vitamin B3, is the
precursor of nicotinamide adenine dinucleotide (NAD), and it
may act as a poly(ADP-ribose) polymerase (PARP) inhibitor.
When ischemia-induced DNA strand breakage is too extensive,
the overactivation of PARP may lead to intracellular NAD
depletion and subsequent secondary energy failure (ie, ATP
depletion).2 ATP levels can be dramatically increased following
ischemia-reperfusion by nicotinamide.3 This scenario is gener-
ally accepted to explain the neuroprotective action of nicotin-
amide. However, it is also well known that high doses of
nicotinamide (250 mg/kg in our case4) increase regional cerebral
blood flow, and many studies have ignored cerebral blood flow.
Therefore, we cannot jump into a conclusion that nicotinamide is
a pure neuroprotectant independent of vasodilative action. If one
does not consider divergent mechanisms of the beneficial effects
of a candidate drug, such a promising drug based on animal
experiments may fail to work under clinical settings, even though
pooling of animal data reveals undoubtedly obvious
neuroprotection.
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Response:
The comments of Yao and colleagues serve to further illustrate
the potential uses of systematic review and meta-analysis in the
context of the interpretation of data from animal studies in stroke.
Studies in focal cerebral ischemia may report measurement of
cerebral blood flow (CBF). In most cases, they find no signifi-
cant differences between control and treated groups, and use this
to infer that any protective effect seen is not a consequence of
changes in CBF. However, power calculations for such compar-
isons are seldom if ever reported; it may be that a true difference
in CBF is missed because studies are underpowered for this
comparison (ie, there is a type II or “false negative” error).
Analyses such as ours can illuminate the impact of study
quality and study design on the estimate of efficacy. Equally,
where data are available the same technique could be used to
give a more precise estimate of the effect of a drug on CBF. This
would reduce the probability of a type II error, and thereby
reduce the risk that protection due to an effect on CBF might be
incorrectly attributed to some other drug property.
It is likely that systematic review and meta-analysis can
provide further insights both into the limits to the efficacy of
individual drugs and into more generic determinants of outcome
in experimental stroke. We are currently developing an interna-
tional collaborative approach to establish priorities for future
research and to develop a standard set of methodologies which
might be used.
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Intravenous Magnesium for Neuroprotection
in Acute Stroke: Clinical Hope Versus
Basic Neuropharmacology
To the Editor:
Saver and colleagues investigated the neuroprotective effect of
early magnesium infusion in ischemic or hemorrhagic stroke in
the field; three quarters of the infarct cohort were treated within
2 hours of onset, and nearly one-third within 1 hour of onset.1
Dramatic early and good results were reported in the early (42%
of 2-hour infarct patients) and 90-day global functional out-
comes (69% of all patients and 75% of 2 hour infarct patients),
respectively. These authors recommend large-scale trials with
field initiation of magnesium for early neuroprotection in stroke.
An essential prerequisite for any pharmacological agent to
offer significant brain neuronal protection during strokes is its
ability to freely cross the blood–brain barrier (BBB). Transport
of magnesium from blood to cerebrospinal fluid across BBB is
limited in normal humans; intravenous administration of magne-
sium sulfate does not increase cerebrospinal fluid magnesium
concentration.2 Orally or intravenously administered magnesium
sulfate cannot affect brain neuronal function.3 Acute stroke is a
hemodynamically highly labile clinical condition and impressive
functional outcomes with magnesium supplementation should be
viewed critically and cautiously.
The adaptive nature of hypomagnesemia, seen in a wide
variety of clinical conditions and circumstances, including hos-
pitalization and diabetes mellitus, is not generally appreciat-
ed.4,5,6 Magnesium impairs cardiac pump function, a physiolog-
ical limitation to rapid therapeutic supplementation in acute
myocardial infarction or congestive heart failure.5 With a mean
patient age of 74 years (range 44 to 92 years) in this trial,1 the
negative inotropic effect of magnesium infusion5 can signifi-
cantly impair cardiac output and cranial perfusion pressure in this
presbycardiac cohort. Informed consent from potential patients
for clinical trials involving magnesium supplementation must
include pharmacokinetic information about magnesium and
BBB. Absence of serious side effects1 does not by itself support
use of any neuroprotective agent. No large-scale trial of magne-
sium supplementation in stroke, in the field or in the hospital,
should be envisaged without presenting this facet of magnesium
pharmacology to the approving institutional review board.
Vinod K. Gupta, MD
Dubai Police Medical Services
Dubai, United Arab Emirates
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Intravenous Magnesium for Neuroprotection
in Acute Stroke: Neuropharmacology
Supports Clinical Hope
Response:
We thank Dr Gupta for his interest in our study, but we
strongly disagree with his assessment of the pertinent literature.
In fact, the basic neuropharmacology of magnesium sulfate
provides substantial support for clinical stroke trials in humans.
Several studies show that magnesium does cross the blood–brain
barrier, in both animals and in humans.1 Brain magnesium concen-
trations are regulated by active blood–brain barrier transport.2,3
Cerebrospinal fluid magnesium concentration increases by 20% to
25% in response to doubling of the serum concentration, and peaks
around 4 hours after parenteral administration.3–5 While this overall
increase in cerebrospinal fluid magnesium concentration is modest,
magnesium concentration is selectively substantially increased in
regions of pathology, including focal ischemia and seizures.6,7
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It is also well known that the mild negative inotropic effect of
magnesium sulfate is offset by its lowering of peripheral vascular
resistance, resulting in no clinically substantial impairment in
cardiac pump function.8,9 Several physiological studies suggest
that magnesium increases cardiac output.10,11 Even in patients
experiencing active myocardial ischemia, magnesium sulfate
showed only a very small increase in the incidence of cardio-
genic shock or congestive heart failure in the large ISIS-4 trial,12
and no adverse effect on cardiac pump function was reported in the
more recent MAGIC clinical trial.13 Most saliently, among stroke
patients in the phase 3 IMAGES trial, there was no excess of cardiac
events related to administration of magnesium sulfate.14
In addition, magnesium sulfate is a potent cerebral vasodilator,
in part due to calcium channel antagonism at vascular smooth
muscle cells and possibly effects on myosin-binding proteins that
regulate contraction.15,16 Consequently, magnesium sulfate typ-
ically increases, rather than decreases, cerebral perfusion.17–19
Magnesium sulfate has been demonstrated to reduce infarct
volume in multiple animal models of stroke, has numerous
identified beneficial neuroprotective and vascular effects, is
already known to be efficacious in treating in humans a condition
characterized by altered cerebral blood flow (eclampsia), and has
shown a potential signal of efficacy when administered early
after stroke onset (within 3 hour subgroup) in a randomized
clinical trial.14 Further trials of magnesium sulfate in early time
epochs in acute stroke are well-supported by preclinical and
clinical neuropharmacology.20
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Surgery Versus Stenting: How Medical Device
Makers Influence Patient Care
To the Editor:
A recent Wall Street Journal article1 highlighted the unfortu-
nate tactics of medical device makers (Medtronic Inc of Minne-
apolis, in this instance) that influence scientific research by
financial incentives to medical consultants who are investigators,
aggressive marketing, and ultimately legal action.
The above article describes the controversial issues surround-
ing stent graft repairs of abdominal aortic aneurysms. It caused
me to recall another equally disturbing debate that exists regard-
ing the most efficacious treatment of carotid stenosis: carotid
endarterectomy (CEA) versus carotid artery stenting (CAS). In a
presentation at the November 2002 American Heart Association
meeting in Chicago, Illinois, Dr Jay Yadav from the Cleveland
Clinic reported the initial results of carotid stenting and angio-
plasty with protection (filters used to trap debris inside the
carotid artery after the plaque is disrupted with a balloon or stent)
in patients at high risk for endarterectomy (SAPPHIRE Study).
The 30-day major adverse clinical event rate (stroke, myocardial
infarction, death) was 5.8% for CAS with protection and 12.6%
for CEA.
In a review by the Performance Improvement Committee at
HCA Wesley Medical Center, an affiliate hospital of the Uni-
versity of Kansas at Wichita, published in the Physicians
Bulletin, 530 CEAs throughout a 24-month period beginning
January 1998 were reviewed.2 These procedures were performed
on patients admitted with the primary diagnosis of carotid
stenosis who underwent CEA. All CEAs were performed by 4
vascular and 8 cardiothoracic surgeons. Included were many
high-risk patients similar to those used in the SAPPHIRE Study:
patients with severe heart disease, emphysema, dialysis-
dependent renal failure, restenosis after previous endarterectomy,
and patients with prior neck irradiation. Same-stay stroke oc-
curred in 1 patient and same-stay mortality (due to myocardial
infarction) occurred in another patient.
Carotid endarterectomy has been one of the most extensively
scrutinized operations of our time.
 90% of patients can undergo operation with preoperative
ultrasound only without arteriography
 90% do not require intensive care monitoring
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 90% require hospital stay of 24 hours or less
 the vast majority require no postoperative restrictions
 arterial complications as a result of arteriography (such as
aneurysm formation) are not pertinent to CEA
 charges are less than that of stent procedures
 recurrent stenosis rates are less than 10%
 combined risk of stroke and death in multiple reports is less
than 3%
The main danger of CAS is distal embolization with resultant
stroke. Many patients without clinical stroke have demonstrated
embolic debris after CAS if studied by various diagnostic
modalities. The majority of patients with significant carotid
stenosis demonstrate plaque hemorrhage, which is prone to
embolize spontaneously without manipulation with a wire or
catheter. Surgeons have much better means of reducing embolic
complications with complete control of arterial blood flow
during operation as opposed to stenting procedures.
With more than 150 000 CEAs performed in the United States
annually, medical device companies have a huge financial
interest in this procedure. Consequently, patients who typically
would have CEA are shifted to stenting. Hospital cost for each
stent alone is approximately $1500 or more, and some patients
require more than one stent. In addition, these procedures
necessitate multiple guide wires, catheters, balloon angioplasty
catheters and protection devices, produced by the same compa-
nies who produce the stents.
The September 2003 edition of Endovascular Today devoted a
section to an update on CAS.3–6 Three of 4 clinical authors were
chief medical editors of the journal and the other author was on
the Editorial Advisory Board. Of these 4 authors, three are
consultants to medical device companies (Cordis, Medtronic, and
Guidant).
Are the reported results of CAS truly unbiased? Many of the
leading investigators are paid consultants of medical device
manufacturers. As a specialist in vascular disease, and specifi-
cally a vascular surgeon, I perform CEAs. I also perform stent
procedures in most peripheral arteries where indicated and stent
graft repairs of abdominal aortic aneurysms. These procedures
are effective and offer patients potentially less morbid alterna-
tives to open operations. On the other hand, CAS offers little
advantage over CEA, a minimally invasive procedure itself.
Theoretically, if one considers the pathology being treated and
the sensitivity of brain tissue to a lack of blood supply, CAS is
difficult to justify. If it is truly safer, I will perform the procedure
like others in my specialty. Nonetheless, in such a potentially
high-risk area, the public deserves meticulous analysis by unbi-
ased investigators who have no financial tie to the results.
Alex D. Ammar, MD
Department of Surgery
University of Kansas School of Medicine
Wichita, Kansas
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Aspirin for Stroke Prevention Taken in
the Evening?
To the Editor:
We read the article by Yip et al1 with great interest, in which
they demonstrated that platelet activation significantly increases
in acute ischemic stroke and subtantially decreases thereafter.
The lesser long-term pharmacodynamic potency of aspirin rela-
tive to clopidogrel raises the prospect of the need for more
effective antiplatelet agents or a synergistic combination therapy
for stroke prevention in the future.1 Their results are very
impressive and raise some ideas, particularly associated with the
prevention’s procedures.
According to World Health Organization data, in 1996 4.6
million people in the world died because of cerebrovascular
manifestation of atherothrombosis.2 In Hungary, nearly 18 000
people suffer stroke every year, half of whom die within a year.
In cases of both cardiovascular and cerebrovascular diseases the
significant decrease of morbidity/mortality can only be achieved
by increasing the effect of prevention. A major form of second-
ary prevention is the administration of drugs inhibiting the
aggregation of platelets.
Aspirin is one of the most common, useful, and inexpensive
tools for prevention. The effect of aspirin on platelets is irrevers-
ible lasting for the duration of the platelet’s life span (10 days).
Aspirin-mediated inhibition of platelet function occurs within 60
minutes of ingestion.3
The incidence of stroke assessed by onset of clinical symp-
toms exhibits a marked circadian variation with a peak period
during the morning. Stroke usually occurs unexpectedly and
more frequently in early morning hours (between 5 to 12 PM; see
Figure) when the aggregability of thrombocytes is higher.4
Relation of plasma serum levels of salicylacid and the daily distribution of the occurrence of acute ischemic stroke. Vertical bar graphs
represent daily distribution of incidence of ischemic stroke.4 Line diagrams show serum level of salicylacid in g/mL taken at 10:00 PM
(dotted line) and at 8:00 AM (solid line). The maximum plasma concentration of salicylacid occurs 3.5 to 4.0 hours after intake.5 Ntotal
number of patients involved in analysis, SAsalicylacid.
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Increased platelet aggregation in the morning and perhaps an
upright posture may account at least in part for the observed
circadian variation of the manifestation of stroke.
For prevention patients usually take aspirin in the morning.
The treatment regimen is 1 tablet (100 mg) per day to be
swallowed without chewing at least 30 minutes before breakfast.
The relation of occurrence of stroke and the change of aspirin’s
plasma level taking in the morning is demonstrated in the Figure.
It is obvious that highest plasma level of the drug occurs after the
morning peak-incidence of the thromboembolic event, suggest-
ing lower prophylactic effect of aspirin. Furthermore, this treat-
ment regimen has its highest protective effect during the day,
when, synergistically, normal physical activity exerts a protec-
tive action on thromboembolic processes. However, this method
of daily aspirin administration has its lowest protective value
against cardiovascular events during the night and early morning,
when the lack of physical activity further augment the cascade of
hemorheological events favoring platelet aggregation and subse-
quent ischemia. In contrast, highest plasma level of aspirin taken
late evening (10:00 PM) would be reached prior to the peak-
incidence of thromboembolic disorders. We are confident that
this time shift in the administration of aspirin would fit better in
the circadian scheme of the occurrence of stroke, thus resulting
in a significantly more effective prevention. To prove the
viability of this concept we propose to set up international,
randomized, multicenter studies.
Ildiko´ Kriszbacher, MSc
Miklo´s Koppa´n, MD, PhD
Jo´zsef Bo´dis, MD, DSc
Institute of Nursing and Clinical Sciences
Faculty of Health Sciences
University of Pe´cs
Pe´cs, Hungary
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Response:
Platelets play a key role in the pathogenesis of atherosclerosis
and arterial thrombosis, which are the major contributors to the
development of ischemic stroke and acute coronary syndrome.1–3
Antiplatelet therapy is now a mainstay of primary and secondary
prevention of death, myocardial infarction, and stroke in various
categories of patients.4–6 Previous studies have demonstrated the
ischemic stroke to display a diurnal variation with a higher
frequency in the early hours of the morning.7,8 Although exactly
why this circadian variation occurs remains uncertain, circadian
variation of fibrinolysis, platelet aggregability, and arterial blood
pressure, with their peak value in the morning, have been
suggested to play a key role in this phenomenon.7–9
Given the safety, widespread availability, and minimal cost of
aspirin therapy, aspirin is one of the most common antiplatelet
agents for secondary prevention following an ischemic stroke.10
Aspirin is rapidly absorbed in the upper gastrointestinal tract and
results in a measurable inhibition of the platelet function within 60
minutes.11 Additionally, a pharmacokinetic study has demonstrated
that the peak serum level of aspirin is generally detected within 3.5
to 4.0 hours following ingestion.12 While considering both the
circadian variation of a stroke and the particular pharmacodynamic
effect of aspirin, Bodis and colleagues conjectured that taking
aspirin in the morning after breakfast, as traditionally recommended,
would offer a lower protective effect on recurrent stroke. They
proposed that aspirin taken in the late evening, ie, around 10:00 PM,
would benefit patients more than aspirin taken during the traditional
administration time. To prove the viability of this hypothesis, they
propose to set up international, randomized, multicenter studies.
We read with great interest regarding their hypothesis and
opinion. However, 3 issues should be considered before conducting
trials to test their hypothesis. First, if taking aspirin in the late
evening could provide additional benefit than taking aspirin in the
morning, a concern may arise over whether taking aspirin (100 mg)
twice daily might be more protective to patients than daily admin-
istration. Second, owing to the benefits of aspirin in treating acute
ischemic stroke,10 acute coronary syndrome,3 and in the secondary
prevention for cardiovascular and cerebrovascular diseases,4 numer-
ous studies have attempted to evaluate aspirin as a primary preven-
tion strategy.5,6,13 While the results regarding the role of aspirin on
the primary prevention of cardiovascular mortality remains incon-
sistent,4,13,14 aspirin does not appear to significantly affect the
primary prevention of a stroke.6,14 These observations motivate the
search for a more effective antiplatelet agent other than aspirin for
primary stroke prevention in the future. Third, several randomized
trials4,5,15 have been conducted to determine the extent of reduction
in terms of cardiovascular outcomes by different antiplatelet thera-
pies in patients at risk of ischemic stroke. Clopidogrel, a new
thienopyridine derivative that is chemically related to ticlopidine,
blocks activation of platelets by selectively and irreversibly inhib-
iting the binding of adenosine diphosphate (ADP) to its receptor on
platelets, subsequently inhibiting the ADP-dependent activation of
the Gp IIb-IIIa complex, the major receptor for fibrinogen binding
on platelet surface.5 A related study has demonstrated that clopi-
dogrel is more effective than aspirin in reducing the combined risk
of ischemic stroke, myocardial infarction, or vascular death.5 Our
study16 has provided basic evidence that clopidogrel is more potent
than aspirin in suppressing platelet activation after ischemic stroke,
and, therefore, further strengthens the conclusions of previous
studies.4,5,15 Although testing the hypothesis whether aspirin admin-
istered in late evening (at 10:00 PM) would offer greater benefit to
patients would be more interesting, identifying a more effective
antiplatelet agent for primary or secondary prevention of ischemic
stroke would be more meaningful.
Hon-Kan Yip, MD
Shun-Sheng Chen, MD, PhD
Mien-Cheng Chen, MD
Department of Internal Medicine
Chang Gung Memorial Hospital
Kaohsiung Hsien, Taiwan, R.O.C.
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Predicting rtPA Associated ICH in
Acute Stroke
To the Editor:
I read with interest the study by Trouillas et al from Lyon,
France,1 describing a plasma marker associated with parenchy-
mal brain hemorrhage in patients treated with intravenous re-
combinant tissue plasminogen activator (rtPA) for acute stroke.
Unusually high D-dimer levels measured at 2 hours after begin-
ning rtPA were associated with increased risk of parenchymal
hemorrhage within 24 hours. This is useful information that
could be translated to patients treated elsewhere with a similar
protocol. However, the currently adopted protocol for intrave-
nous rtPA treatment of acute stroke in the United States and
many other countries is according to the American Stroke
Association (ASA)2 and the American Academy of Neurology
(AAN)3 guidelines, and these guidelines differ in 2 important
ways from the protocol used in Lyon. I would like to point out
that because of these differences, the findings from Lyon may not
translate to centers that follow the ASA/AAN guidelines.
First, the ASA/AAN guidelines do not recommend treatment
beyond 3 hours after symptom onset, compared with up to 7
hours in Lyon. The mean delay to starting intravenous rtPA in
Lyon was nearly 4 hours (based on a previous publication from
that center),4 which is approximately 90 minutes later than in the
United States. This difference may be important as longer
exposure to brain ischemia, with greater injury to the blood
vessels and surrounding tissue, may predispose to hemorrhagic
complications more than shorter exposure.
Second, the ASA/AAN guidelines advise against anticoagula-
tion within 24 hours after rtPA treatment, compared with
anticoagulation immediately after rtPA infusion in a considerable
proportion of the patients in Lyon (exact proportion not stated).
Anticoagulation is a well-established risk for parenchymal brain
hemorrhage in multiple settings.
Thus, elevated D-dimer levels in acute stroke patients treated
with intravenous rtPA according to the ASA/AAN guidelines
may not be predictive of parenchymal hemorrhage, as they are in
patients treated with the Lyon study protocol. It would be useful
to validate the findings from Lyon in patients treated within the
ASA/AAN guidelines.
Askiel Bruno, MD
Department of Neurology
Stroke Program
Indiana University School of Medicine
Indianapolis, Indiana
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We have been interested by the constructive remarks of Dr
Bruno, who points out the need of further studies on hemostasis
in rtPA protocols using ASA/AAN guidelines, in order to
confirm the predictive value of degradation factors. Some clari-
fications must, however, be given.
First, in our study,1 we measured fibrin(ogen) degradation
products (FDP), which involve fragments of fibrinogen and
fibrin, while D-dimers originate exclusively from fibrin.2 This
postthrombolytic increase of FDP at 2 hours (early fibrinogen
degradation coagulopathy) was correlated with a fibrinogen
decrease, indicating an impact of rtPA, at least partial, on
circulating fibrinogen. It may be possible that D-dimers, which
have a different biological significance, would not be predictive
of early parenchymal hematoma. However, this measurement is
now included in our prospective hemostasis evaluation.
Second, the Lyon protocol3,4 was designed in 1993, before the
NINDS rtPA Study4 was published. At that time, the dose of
rtPA, the window of administration, and the anticoagulant
regimens were not standardized. However, the dose chosen was
remarkably similar to that of the NINDS study (0.8 mg/kg). After
the publication of the NINDS study results, we decided to
continue the trial up to 200 patients, because our protocol was the
unique opportunity to know what gave a slightly lower rtPA dose
with a longer infusion time (90 minutes), a wider time window (7
hours), and precise postthrombolytic heparin regimens. In the
cohort of 157 patients with hemostasis screening,1 the rate of
symptomatic hemorrhage (3.8%) was lower than in part 1 (6%)
and in part 2 (7%) of the NINDS study.4 Thus, the hemostasis
disturbances that we described are not linked to a more intense
hemorrhagic process.
Third, the postthrombolytic FDP coagulopathy does not seem
to be influenced by heparin. In our cohort, only 20.3% of patients
had a regimen with immediate postthrombolytic unfractionated
heparin. In several myocardial infarction trials including imme-
diate use of intravenous heparin, an early FDP increase took
place and was demonstrated to be correlated with bleeding
complications, general or cerebral.5–11
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Thus, there is a chance that early fibrinogen degradation
coagulopathy, predictive of early parenchymal hematomas, may
be confirmed in rtPA protocols following the ASA/AAN guide-
lines, without heparin during the 24 first hours, as well as in
intraarterial protocols like PROACT II using postthrombolytic
heparin.12 Another answer may be given by the FRALYSE
study, ongoing in France: this randomized, assessment blinded
study, compares arms with the NINDS and Lyon protocols, with
hemostasis and clinical parameters.
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